Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
CDC shrinks childhood vaccine recommendation list to mirror “peer nations”
The US Centers for Disease Control (CDC) has shifted its stance on childhood vaccination, having minimised its routine recommendation list…
-
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will…
-
Revamping best-selling drugs to combat patent cliff has limits
As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making…
-
Alternative commercialisation models offer lifeline to future of gene therapies
Cell and gene therapies (CGTs) have captured significant interest in the pharma industry, with the modality being explored in multiple…
-
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies…
-
AstraZeneca pulls Andexxa from US market after post-marketing fatalities
AstraZeneca has pulled its anticoagulant therapy, Andexxa (recombinant coagulation factor Xa), from the US market after patient fatalities. This follows…
-
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients…
-
FDA approves meningioma label warning on Pfizer’s contraceptive injection
The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which…
-
GSK obtains FDA approval for Exdensur in severe asthma
GSK has secured approval from the US Food and Drug Administration (FDA) for its severe asthma add-on maintenance therapy, Exdensur…